Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Preclinical safety evaluation of subconjunctival methotrexate in the rabbit model.

Created on 13 Jul 2026

Authors

Raj Savla, Manisha Malani, Soumyava Basu, Jayabalan Nirmal

Published in

Cutaneous and ocular toxicology. Pages 1-9. Jul 12, 2026. Epub Jul 12, 2026.

Abstract

To assess the safety of subconjunctival methotrexate in New Zealand White rabbits.
The New Zealand white rabbits received subconjunctival injections of methotrexate in the right eye with amounts of 400, 800, 1600, and 3200 μg. Slit lamp biomicroscopy and corneal fluorescein staining were used to assess the anterior segment of the eye. Vitreous haze and fundus abnormalities were evaluated using slit lamp indirect ophthalmoscopy. The intraocular pressure was measured using a rebound tonometer. After 30 days of methotrexate administration, the rabbits were sacrificed, and their eyeballs were enucleated for histological analysis.
Upon examination, no obvious changes were observed in the anterior and posterior segments of the eye. The intraocular pressure levels of the injected eye, prior to and after injections, did not show any significant difference. Furthermore, the ocular tissue displayed no signs of histological alterations.
Methotrexate injected via the subconjunctival route (up to 3200 μg) was found to be safe and well-tolerated in the rabbit model. However, future investigations are required to assess the pharmacokinetics and therapeutic efficacy in the disease-specific animal model.

PMID:
42437500
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement